91 related articles for article (PubMed ID: 8587415)
1. Potency of PD155080, an orally active ETA receptor antagonist, determined for human endothelin receptors.
Maguire JJ; Kuc RE; Doherty AM; Davenport AP
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S362-4. PubMed ID: 8587415
[TBL] [Abstract][Full Text] [Related]
2. Characterization of [125I]-PD164333, an ETA selective non-peptide radiolabelled antagonist, in normal and diseased human tissues.
Davenport AP; Kuc RE; Ashby MJ; Patt WC; Doherty AM
Br J Pharmacol; 1998 Jan; 123(2):223-30. PubMed ID: 9489609
[TBL] [Abstract][Full Text] [Related]
3. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.
Maguire JJ; Davenport AP
Br J Pharmacol; 1995 May; 115(1):191-7. PubMed ID: 7647976
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of endothelin-1 and characterization of the selective endothelin a receptor antagonist PD155080 in the prostate.
Imajo C; Walden PD; Shapiro E; Doherty AM; Lepor H
J Urol; 1997 Jul; 158(1):253-7. PubMed ID: 9186370
[TBL] [Abstract][Full Text] [Related]
5. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors.
Maguire JJ; Bacon CR; Fujimoto M; Davenport AP
J Hypertens; 1994 Jun; 12(6):675-80. PubMed ID: 7963492
[TBL] [Abstract][Full Text] [Related]
6. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle.
Davenport AP; O'Reilly G; Molenaar P; Maguire JJ; Kuc RE; Sharkey A; Bacon CR; Ferro A
J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S22-5. PubMed ID: 7509950
[TBL] [Abstract][Full Text] [Related]
7. Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors.
Maguire JJ; Kuc RE; Davenport AP
J Pharmacol Exp Ther; 1997 Feb; 280(2):1102-8. PubMed ID: 9023329
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.
Peter MG; Davenport AP
Br J Pharmacol; 1996 Feb; 117(3):455-462. PubMed ID: 8821534
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists.
Fukami T; Nagase T; Fujita K; Hayama T; Niiyama K; Mase T; Nakajima S; Fukuroda T; Saeki T; Nishikibe M
J Med Chem; 1995 Oct; 38(21):4309-24. PubMed ID: 7473559
[TBL] [Abstract][Full Text] [Related]
10. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.
Davenport AP; O'Reilly G; Kuc RE
Br J Pharmacol; 1995 Mar; 114(6):1110-6. PubMed ID: 7620699
[TBL] [Abstract][Full Text] [Related]
11. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles.
Lanese DM; Conger JD
J Clin Invest; 1993 May; 91(5):2144-9. PubMed ID: 8486781
[TBL] [Abstract][Full Text] [Related]
12. Endothelin-1-evoked calcium transients in UMR-106 osteoblastic osteosarcoma cells are mediated through endothelin-A and endothelin-B receptors.
Semler DE; Ohlstein EH; Nambi P; Slater C; Stern PH
J Pharmacol Exp Ther; 1995 Mar; 272(3):1052-8. PubMed ID: 7891315
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670.
Ohlstein EH; Beck GR; Douglas SA; Nambi P; Lago MA; Gleason JG; Ruffolo RR; Feuerstein G; Elliott JD
J Pharmacol Exp Ther; 1994 Nov; 271(2):762-8. PubMed ID: 7965794
[TBL] [Abstract][Full Text] [Related]
14. Endothelin-1 mediated inhibition of the acetylcholine-activated potassium current from rabbit isolated atrial cardiomyocytes.
Spiers JP; Kelso EJ; McDermott BJ; Scholfield CN; Silke B
Br J Pharmacol; 1996 Dec; 119(7):1427-37. PubMed ID: 8968552
[TBL] [Abstract][Full Text] [Related]
15. Binding and functional properties of endothelin receptor subtypes in the human prostate.
Kobayashi S; Tang R; Wang B; Opgenorth T; Langenstroer P; Shapiro E; Lepor H
Mol Pharmacol; 1994 Feb; 45(2):306-11. PubMed ID: 8114678
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of human endothelin receptors ETA and ETB identification of regions involved in the selectivity for endothelin 3 or cyclo-(D-Trp-D-Asp-Pro-D-Val-Leu).
Becker A; Haendler B; Hechler U; Schleuning WD
Eur J Biochem; 1994 May; 221(3):951-8. PubMed ID: 8181477
[TBL] [Abstract][Full Text] [Related]
17. Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments.
Maguire JJ; Kuc RE; Rous BA; Davenport AP
Br J Pharmacol; 1996 May; 118(2):335-42. PubMed ID: 8735635
[TBL] [Abstract][Full Text] [Related]
18. Hyperresponsiveness to ET-1 after treatment with a mixture of ETA and ETB receptor antagonists in the rabbit in vivo and in vitro.
D'Orléans-Juste P; Yano M; Maurice MC; Gratton JP
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S369-72. PubMed ID: 8587417
[TBL] [Abstract][Full Text] [Related]
19. [125I]-PD151242: a selective radioligand for human ETA receptors.
Davenport AP; Kuc RE; Fitzgerald F; Maguire JJ; Berryman K; Doherty AM
Br J Pharmacol; 1994 Jan; 111(1):4-6. PubMed ID: 8012722
[TBL] [Abstract][Full Text] [Related]
20. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart.
Molenaar P; Kuc RE; Davenport AP
Br J Pharmacol; 1992 Nov; 107(3):637-9. PubMed ID: 1472961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
